Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

971 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Clinical characteristics, risk factors, and incidence of symptomatic coronavirus disease 2019 in a large cohort of adults living with HIV: a single-center, prospective observational study.
Inciarte A, Gonzalez-Cordon A, Rojas J, Torres B, de Lazzari E, de la Mora L, Martinez-Rebollar M, Laguno M, Callau P, Gonzalez-Navarro A, Leal L, Garcia F, Mallolas J, Mosquera M, Marcos MA, Ambrosioni J, Miro JM, Martinez E, Blanco JL; (on behalf the COVID-19 in HIV Investigators). Inciarte A, et al. Among authors: miro jm. AIDS. 2020 Oct 1;34(12):1775-1780. doi: 10.1097/QAD.0000000000002643. AIDS. 2020. PMID: 32773471 Free PMC article.
Prevalence of HTLV-1/2 infections in Spain: A cross-sectional hospital-based survey.
Treviño A, García J, de Mendoza C, Benito R, Aguilera A, Ortíz de Lejarazu R, Ramos JM, Trigo M, Eirós JM, Rodríguez-Iglesias M, Torres A, Calderón E, Hernandez A, Gomez C, Marcaida G, Soriano V; HTLV Spanish Study Group. Treviño A, et al. AIDS Res Hum Retroviruses. 2010 Aug;26(8):861-4. doi: 10.1089/aid.2009.0234. AIDS Res Hum Retroviruses. 2010. PMID: 20672999
A new multidisciplinary home care telemedicine system to monitor stable chronic human immunodeficiency virus-infected patients: a randomized study.
León A, Cáceres C, Fernández E, Chausa P, Martin M, Codina C, Rousaud A, Blanch J, Mallolas J, Martinez E, Blanco JL, Laguno M, Larrousse M, Milinkovic A, Zamora L, Canal N, Miró JM, Gatell JM, Gómez EJ, García F. León A, et al. Among authors: miro jm. PLoS One. 2011 Jan 21;6(1):e14515. doi: 10.1371/journal.pone.0014515. PLoS One. 2011. PMID: 21283736 Free PMC article. Clinical Trial.
Epidemiological characteristics and predictors of late presentation of HIV infection in Barcelona (Spain) during the period 2001-2009.
de Olalla PG, Manzardo C, Sambeat MA, Ocaña I, Knobel H, Humet V, Domingo P, Ribera E, Guelar A, Marco A, Belza MJ, Miró JM, Caylà JA; HIV Surveillance Group. de Olalla PG, et al. Among authors: miro jm. AIDS Res Ther. 2011 Jul 6;8(1):22. doi: 10.1186/1742-6405-8-22. AIDS Res Ther. 2011. PMID: 21729332 Free PMC article.
Intensification of a raltegravir-based regimen with maraviroc in early HIV-1 infection.
Puertas MC, Massanella M, Llibre JM, Ballestero M, Buzon MJ, Ouchi D, Esteve A, Boix J, Manzardo C, Miró JM, Gatell JM, Clotet B, Blanco J, Martinez-Picado J; MaraviBoost Collaborative Group. Puertas MC, et al. Among authors: miro jm. AIDS. 2014 Jan 28;28(3):325-34. doi: 10.1097/QAD.0000000000000066. AIDS. 2014. PMID: 24185044 Clinical Trial.
A case of Mycoplasma hominis disseminated infection in a human immunodeficiency virus-1-infected pregnant woman with hypogammaglobulinemia.
Fernández S, Nicolás D, Pericás JM, Castro Rebollo P, Vila J, Miró JM, Blanco JL, Nicolás JM. Fernández S, et al. Among authors: miro jm. J Microbiol Immunol Infect. 2017 Feb;50(1):118-119. doi: 10.1016/j.jmii.2014.11.006. Epub 2014 Nov 25. J Microbiol Immunol Infect. 2017. PMID: 25648665 Free article. No abstract available.
Mortality, Causes of Death and Associated Factors Relate to a Large HIV Population-Based Cohort.
Garriga C, García de Olalla P, Miró JM, Ocaña I, Knobel H, Barberá MJ, Humet V, Domingo P, Gatell JM, Ribera E, Gurguí M, Marco A, Caylà JA; Barcelona HIV/AIDS working group. Garriga C, et al. Among authors: miro jm. PLoS One. 2015 Dec 30;10(12):e0145701. doi: 10.1371/journal.pone.0145701. eCollection 2015. PLoS One. 2015. PMID: 26716982 Free PMC article.
A randomized clinical trial comparing ritonavir-boosted lopinavir versus maraviroc each with tenofovir plus emtricitabine for post-exposure prophylaxis for HIV infection.
Leal L, León A, Torres B, Inciarte A, Lucero C, Mallolas J, Laguno M, Martínez-Rebollar M, González-Cordón A, Manzardo C, Rojas J, Pich J, Arnaiz JA, Gatell JM, García F; MARAVIPEP Study Group. Leal L, et al. J Antimicrob Chemother. 2016 Jul;71(7):1982-6. doi: 10.1093/jac/dkw048. Epub 2016 Mar 18. J Antimicrob Chemother. 2016. PMID: 26994091 Clinical Trial.
Tenofovir disoproxil fumarate/emtricitabine plus ritonavir-boosted lopinavir or cobicistat-boosted elvitegravir as a single-tablet regimen for HIV post-exposure prophylaxis.
Inciarte A, Leal L, González E, León A, Lucero C, Mallolas J, Torres B, Laguno M, Rojas J, Martínez-Rebollar M, González-Cordón A, Cruceta A, Arnaiz JA, Gatell JM, García F; STRIBPEP Study Group. Inciarte A, et al. J Antimicrob Chemother. 2017 Oct 1;72(10):2857-2861. doi: 10.1093/jac/dkx246. J Antimicrob Chemother. 2017. PMID: 29091217 Clinical Trial.
971 results